AuditLine › HHS OIG › Food and Drug Administration
HHS OIG recommendation 19-E-01-018.01
FDA should further communicate to hospitals the importance of obtaining NPS compounded drugs from outsourcing facilities.
The recommendation, in the publisher's words
FDA should further communicate to hospitals the importance of obtaining NPS compounded drugs from outsourcing facilities.
- Responsible agency
- Food and Drug Administration
- Issued
- June 7, 2019
- Report
- Most Hospitals Obtain Compounded Drugs From Outsourcing Facilities, Which Must Meet FDA Quality Standards (OEI-01-17-00090) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Concur (as recorded by the publisher)
- Closed
- April 5, 2021 (publisher's date)
- Publisher topics
- Food; Drug and Device Safety, Hospitals, Prescription Drug, Public Health Issues, Quality of Care
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
1 more, of which 0 are open in the publisher's file.
- FDA should take appropriate followup action with the unregistered compounding facilities on the list that we provided.HHS OIG 19-E-01-018.02 · issued Jun 7, 2019 · closed Apr 5, 2021Closed Implemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.